Niagen Bioscience, Inc Stock Price, News & Analysis

Niagen Bioscience (NASDAQ: NAGE) announced on December 22, 2025 that it acquired the core nicotinamide riboside (NR) patent portfolio from Queen’s University Belfast, making Niagen the sole owner of foundational NR intellectual property.

The portfolio includes composition-of-matter patents (including U.S. Patent No. 12,252,506 covering multiple NR salt forms such as NR Malate and NR Tartrate), methods of making NR, and global rights across multiple jurisdictions. Niagen says the move strengthens its >90 issued and pending patents estate, including >50 focused on NR, and provides greater strategic, operational and licensing optionality for current and future pharmaceutical and other applications.

Niagen Bioscience (NASDAQ: NAGE) launched Tru Niagen® Beauty, the first U.S. NAD+ skincare supplement featuring Niagen (patented nicotinamide riboside).

Each capsule delivers 100 mg Niagen plus clinically studied actives: Astaxanthin 4 mg, Hyaluronic acid 120 mg, Grape seed extract 100 mg, Biotin 5 mg, and Vitamin E 30 mg. The product is sold at $62 one-time or $49.60 subscription, with bundles combining Tru Niagen 300 mg and Tru Niagen Pro 1,000 mg. Tru Niagen Beauty ships direct at truniagen.com and will launch on the healthcare practitioner channel on February 2, 2026. Market context includes astaxanthin and nutricosmetics growth projections cited for industry demand.

Niagen Bioscience (NASDAQ: NAGE) reported results from a randomized, double-blind, placebo-controlled trial (58 participants) published in eClinicalMedicine on November 13, 2025 testing Niagen® nicotinamide riboside (NR) in long COVID. Participants received 2,000 mg/day NR for 20 weeks (placebo 10 weeks then NR 10 weeks). Whole-blood NAD+ levels rose up to 3.1-fold after 5–10 weeks. Post-hoc within-group improvements were seen in fatigue, sleep quality, and depressive symptoms after 10 weeks. No statistically significant differences were observed between NR and placebo for primary or secondary endpoints, and the study cited limited power due to small sample size and dropouts. NR was well tolerated with no significant adverse-event differences.

Niagen Bioscience (NASDAQ: NAGE) announced that its Board approved a $10 million share repurchase program to buy back common stock over approximately 24 months. The company may repurchase shares in the open market, through privately negotiated transactions, or by other means, subject to law and market conditions. Timing, method, pricing, and amounts will be determined by management and there is no obligation to repurchase shares. The Program may be modified, suspended, or terminated at any time without prior notice. Management described the Program as a compelling use of company capital. For more information, visit the company website.

Niagen Bioscience (NASDAQ:NAGE) reported third-quarter 2025 results with net sales up 33% to $34.0M and Tru Niagen sales $26.0M (+44%). Net income was $4.6M ($0.06/share) versus $1.9M a year ago, and Adjusted EBITDA rose 120% to $6.4M. Cash from operations for the nine months was $12.8M, with quarter-end cash of $64.3M. The company reaffirmed and raised full-year 2025 net sales guidance to +25%–30% YoY. Operational highlights include the launch of the AboutNAD digital platform, a favorable National Advertising Division decision, and expansion of Niagen Plus distribution to >1,000 clinics. Updated expense outlooks include higher G&A ($8.0–$9.0M).

Niagen Bioscience (NASDAQ: NAGE) will report third quarter 2025 financial results for the period ended September 30, 2025, after market close on Tuesday, November 4, 2025. Management will host an investor conference call on Tuesday, November 4, 2025 at 4:30 p.m. ET to discuss the results and provide a general business update.

Call participants should dial in at least 10 minutes early. Toll-free dial-in: +1 888 596 4144 with Conference ID 8584242. A live webcast will be available on the company investor relations site and a replay will be available from 7:30 p.m. ET on November 4, 2025 through 11:59 p.m. ET on November 11, 2025 (toll-free replay +1 800 770 2030, Replay ID 8584242).

Niagen Bioscience (NASDAQ: NAGE) has expanded the availability of its pharmaceutical-grade Niagen Plus™ products to over 900 clinics nationwide, including more than 50 iCRYO locations. The company's Niagen IV and injections, which boost NAD+ levels, demonstrated superior performance compared to traditional NAD+ IV therapy in clinical studies, featuring 75% shorter infusion times and a 20% increase in whole blood NAD+ levels.

The partnership with iCRYO aligns with both companies' focus on preventative health solutions and longevity. Niagen's nicotinamide riboside (NR) is clinically validated as the most efficient NAD+ booster, addressing the natural decline of NAD+ levels associated with aging and stress. The treatment supports cellular function, metabolic health, and overall well-being.

Niagen Bioscience (NASDAQ: NAGE) has launched an enhanced version of AboutNAD®, a comprehensive online platform dedicated to NAD+ science and research. The website serves as a centralized educational resource focusing on nicotinamide riboside (NR), featuring peer-reviewed studies and scientific advancements in NAD+ biology.

The platform includes a categorized research database, advanced search functionality, expert perspectives, and scientific newsletters. Content is structured around three core principles: evidence-based research, accessibility, and community orientation, aiming to bridge the gap between scientific research and public understanding of NAD+ biology and its role in healthy aging.